FIELD: pharmaceutics.
SUBSTANCE: group of inventions refers to chemical-pharmaceutical industry, namely to bioconjugates for producing agent for treating malignant pathologies, consisting of hyaluronic acid with molecular weight ranging from 30,000 to 0.5×106 Da covalently connected via spacer, selected from bromebutanol or bromepropanol and which forms ester bond with hyaluronic acid, with anti-cancer drug, which represents doxorubicin, with degree of substitution doxorubicin at carboxyl group of hyaluronic acid from 3 to 20 %, and pharmaceutical compositions containing above bioconjugates.
EFFECT: higher cytotoxic activity against tumour cells.
14 cl, 15 ex, 15 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-TUMOUR BIOCONJUGATES OF HYALURONIC ACID OR ITS DERIVATIVES, OBTAINED BY INDIRECT CHEMICAL CONJUGATION | 2006 |
|
RU2411958C2 |
| METHODS OF TREATING CANCER, HAVING HEMIZYGOUS LOSS OF TP53 | 2016 |
|
RU2721953C2 |
| IMPROVED METHODS FOR TREATING TUMOURS | 2007 |
|
RU2481853C2 |
| ANTI-INFLAMMATORY MEDICATION WITH ANTICOAGULANT, ANTITUMOUR AND ANTIMETASTETIC ACTIVITY | 2009 |
|
RU2412712C1 |
| CONJUGATE OF ANTITUMOUR DRUGS WITH RECOMBINANT ALPHA-FETOPROTEIN AND ITS FUNCTIONAL FRAGMENTS AND METHOD OF THEIR PRODUCING | 2016 |
|
RU2630974C1 |
| CONJUGATE CONTAINING FOLIC ACID AND INDOLE-3-CARBINOL FOR MEDICAL USE | 2014 |
|
RU2692078C2 |
| CARRIER SYSTEM ON PROTEIN BASE FOR OVERCOMING RESISTANCE OF TUMOUR CELLS | 2006 |
|
RU2404916C2 |
| SODIUM COBALT POLYGALACTURONATE WITH ANTITUMOR ACTIVITY | 2023 |
|
RU2794885C1 |
| CAMPTOTECIN DERIVATIVES AND APPLICATION THEREOF | 2007 |
|
RU2411244C2 |
| METHOD OF SYNTHESISING CONJUGATES OF GLYCOSEAMINOGLYCANES (GAG) WITH BIOLOGICALLY ACTIVE MOLECULES, POLYMER CONJUGATES AND THEIR RESPECTIVE APPLICATIONS | 2010 |
|
RU2530649C2 |
